Table 1.

Baseline demographic, clinical, and laboratory characteristics in CNO at initiation of infliximab or NSAID. Continuous variables expressed as median (range).

VariablesIFX + MTX, n = 9NSAID, n = 9
Age at diagnosis, yrs11 (7–18)11 (7–14)
Sex, female, n68
Race, white, n99
Laboratory studies
  WBC, 1000/µl7.4 (4.6–11.2)7.6 (5.6–11.6)
  Hemoglobin, g/dl12.5 (10.9–15.1)12.3 (10.6–15.1)
  Platelets, 1000/µl423 (228–595)473 (293–694)
  ESR, mm/h15 (4–58)17 (0–115)
  CRP, mg/dl0.8 (0.5–3.5)0.8 (0.2–25.8)
Bone biopsy obtained, n77
Bone culture obtained, n55
Bone lesion sites, n
  Spine43
  Pelvis66
  Clavicle20
  Long bones48
  Mandible10
Prior medications, n
  None22
  Antibiotics37
  NSAID60
  Prednisone20
  Methotrexate10
  Bisphosphonate10
  Other TNF-α inhibitor10
  • CNO: chronic nonbacterial osteomyelitis; IFX: infliximab; MTX: methotrexate; NSAID: nonsteroidal antiinflammatory drugs; WBC: white blood cells; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TNF: tumor necrosis factor.